ReNeuron Group PLC

ReNeuron Group PLC

  • Price (EUR)0.171
  • Today's Change-0.079 / -31.60%
  • Shares traded0.00
  • 1 Year change-83.71%
  • Beta--
Data delayed at least 15 minutes, as of Dec 02 2022.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company’s stem cell derived Exosome Technology platform offers a delivery mechanism for a variety of payloads, such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. The Company has two clinical-stage stem cell therapy candidate assets, a Phase 2a human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa and a Phase 2b immortalized neural progenitor cell therapy candidate (CTX) in stroke. The Company through its induced pluripotent stem cell (iPSC) platform has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

  • Revenue in GBP (TTM)403.00k
  • Net income in GBP-9.69m
  • Incorporated2005
  • Employees36.00
  • Location
    ReNeuron Group PLCPencoed Business ParkBRIDGEND CF35 5HYUnited KingdomGBR
  • Phone+44 203 819 8400
  • Fax+44 148 353 4864
  • Websitehttp://www.reneuron.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.